A Case of Myeloid Neoplasm with a PDGFRB Rearrangement and Eosinophilia.
- Author:
Nam Gil CHO
1
;
Daejin KIM
;
Minjung SHIM
;
So Young CHONG
Author Information
- Publication Type:Case Report
- Keywords: Myeloproliferative disorder; PDGFRB; Eosinophilia; Imatinib mesylate
- MeSH: Bone Marrow; Diagnosis; Eosinophilia*; Fluorescence; Gene Rearrangement; Humans; Imatinib Mesylate; In Situ Hybridization; Leukemia, Myelomonocytic, Chronic; Mass Screening; Middle Aged; Myeloproliferative Disorders; Receptor, Platelet-Derived Growth Factor beta*; Receptors, Platelet-Derived Growth Factor
- From:Korean Journal of Medicine 2017;92(1):79-83
- CountryRepublic of Korea
- Language:Korean
- Abstract: Myeloid neoplasia with eosinophilia and platelet-derived growth factor receptor beta (PDGFRB) rearrangements is an uncommon Philadelphia-negative myeloproliferative neoplasm. Their most common morphological diagnosis is chronic myelomonocytic leukemia with eosinophilia, which is associated with t(5;12)(q33;p13) and results in the formation of the ETV6-PDGFRB fusion gene. Here, we report a 49-year-old man with a myeloid neoplasm with a PDGFRB rearrangement, who was incidentally diagnosed with hyperleukocytosis and eosinophilia during a health screening. A chromosome analysis of a bone marrow sample revealed 46, XY, t(5;12)(q33;p13), and fluorescence in situ hybridization analysis revealed the PDGFRB gene rearrangement. The patient was treated with imatinib and subsequently achieved complete hematological and molecular remission.
